Moreover, ALS-specific pharmacoresistance mechanisms have been identified, with selective upregulation of drug efflux transporters in the SOD1 G93A mouse model [32], reinforcing the relevance of MDR1 inhibition in ALS therapy. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.